Literature DB >> 9259265

The survival motor neuron protein in spinal muscular atrophy.

D D Coovert1, T T Le, P E McAndrew, J Strasswimmer, T O Crawford, J R Mendell, S E Coulson, E J Androphy, T W Prior, A H Burghes.   

Abstract

The 38 kDa survival motor neuron (SMN) protein is encoded by two ubiquitously expressed genes: telomeric SMN (SMN(T)) and centromeric SMN (SMN(C)). Mutations in SMN(T), but not SMN(C), cause proximal spinal muscular atrophy (SMA), an autosomal recessive disorder that results in loss of motor neurons. SMN is found in the cytoplasm and nucleus. The nuclear form is located in structures termed gems. Using a panel of anti-SMN antibodies, we demonstrate that the SMN protein is expressed from both the SMN(T) and SMN(C) genes. Western blot analysis of fibroblasts from SMA patients with various clinical severities of SMA showed a moderate reduction in the amount of SMN protein, particularly in type I (most severe) patients. Immunocytochemical analysis of SMA patient fibroblasts indicates a significant reduction in the number of gems in type I SMA patients and a correlation of the number of gems with clinical severity. This correlation to phenotype using primary fibroblasts may serve as a useful diagnostic tool in an easily accessible tissue. SMN is expressed at high levels in brain, kidney and liver, moderate levels in skeletal and cardiac muscle, and low levels in fibroblasts and lymphocytes. In SMA patients, the SMN level was moderately reduced in muscle and lymphoblasts. In contrast, SMN was expressed at high levels in spinal cord from normals and non-SMA disease controls, but was reduced 100-fold in spinal cord from type I patients. The marked reduction of SMN in type I SMA spinal cords is consistent with the features of this motor neuron disease. We suggest that disruption of SMN(T) in type I patients results in loss of SMN from motor neurons, resulting in the degeneration of these neurons.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259265     DOI: 10.1093/hmg/6.8.1205

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  253 in total

1.  Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).

Authors:  Y Hofmann; C L Lorson; S Stamm; E J Androphy; B Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 2.  Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression.

Authors:  Zhi-Ming Zheng
Journal:  J Biomed Sci       Date:  2004 May-Jun       Impact factor: 8.410

3.  Post-transcriptional modification of spliceosomal RNAs is normal in SMN-deficient cells.

Authors:  Svetlana Deryusheva; Maria Choleza; Adrien Barbarossa; Joseph G Gall; Rémy Bordonné
Journal:  RNA       Date:  2011-11-28       Impact factor: 4.942

4.  Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction.

Authors:  Rocky G Gogliotti; Katharina A Quinlan; Courtenay B Barlow; Christopher R Heier; C J Heckman; Christine J Didonato
Journal:  J Neurosci       Date:  2012-03-14       Impact factor: 6.167

Review 5.  Spinal muscular atrophy: new and emerging insights from model mice.

Authors:  Gyu-Hwan Park; Shingo Kariya; Umrao R Monani
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

6.  Multiple effects of curcumin on promoting expression of the exon 7-containing SMN2 transcript.

Authors:  Dairong Feng; Yi Cheng; Yan Meng; Liping Zou; Shangzhi Huang; Jiuyong Xie
Journal:  Genes Nutr       Date:  2015-09-19       Impact factor: 5.523

7.  Refined characterization of the expression and stability of the SMN gene products.

Authors:  Jérémie Vitte; Coralie Fassier; Francesco D Tiziano; Cécile Dalard; Sabrina Soave; Natacha Roblot; Christine Brahe; Pascale Saugier-Veber; Jean Paul Bonnefont; Judith Melki
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

8.  Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts.

Authors:  Leigh A Skordis; Matthew G Dunckley; Baigong Yue; Ian C Eperon; Francesco Muntoni
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

Review 9.  Spinal muscular atrophy.

Authors:  Susan T Iannaccone; Stephen A Smith; Louise R Simard
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

10.  Molecular diagnosis of spinal muscular atrophy.

Authors:  H Stewart; A Wallace; J McGaughran; R Mountford; H Kingston
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.